Montelukast Sandoz (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This prevents leukotriene D4 from binding, which in turn reduces bronchoconstriction, mucus production, and inflammatory cell recruitment in the airways, leading to better respiratory function.

The appropriate dose of Montelukast is determined by a qualified prescriber based on the patient’s age, condition, and clinical response. Healthcare professionals follow approved labeling and individual patient needs when setting the regimen.

Safety data for Montelukast during pregnancy are limited, so it should only be used when the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding because the drug can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. It is especially useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a non‑inhaled option, though it is generally used as add‑on therapy rather than a sole replacement.

Montelukast tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Montelukast is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, and the dose is typically taken once daily at the same time each day for consistent blood levels.

Serious risks include neuropsychiatric events such as agitation, depression, or suicidal thoughts, as well as severe allergic reactions like rash, angioedema, or anaphylaxis. Rare hepatic injury may also occur, so any signs of liver dysfunction should be reported promptly.

Montelukast should not be used by individuals with a known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe liver impairment, and it is generally avoided in patients where alternative therapies are more appropriate based on clinical judgment.